News for Madrigal Pharmaceuticals, Inc. (MDGL)

Summary Madrigal Pharmaceuticals Inc (MDGL), a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH),

Madrigal Pharmaceuticals (MDGL) to release Q1 2025 results on May 1 before U.S. markets open. Live webcast scheduled at 8 a.m. Eastern Time to discuss f

Madrigal Pharmaceuticals (MDGL) has announced a significant leadership change, with Dr. Rebecca Taub, the company's founder and a pivotal figure in its research

\n Madrigal Pharmaceuticals announces leadership transition as David Soergel, M.D. joins as Chief Medical Officer. Company founder Rebecca Taub, M.D. will beco

\nDr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH\n\nCONSHOHOCKEN, Pa., April 16, 2025 (GLOB

**media[596619]**

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals

Significant Stock Acquisition by Avoro Capital Advisors LLC (Trades, Portfolio) On February 28, 2025, Avoro Capital Advisors LLC (Trades, Portfolio) executed a

High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals MDGL, and it's important for retail traders to take note. \This activity c...

Net Sales (Q4 2024): $103.3 million, reflecting 66% quarter-over-quarter growth.Net Sales (Full Year 2024): $180.1 million, achieved in nine months of commerci

Feb 26, 2025 / 01:00PM GMTOperator Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (O

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Read more here.

The following slide deck was published by Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ETCompany ParticipantsTina Ventura - Chief Investor...

Quarterly Revenue: Achieved $103.3 million in net sales for Rezdiffra, surpassing the estimated revenue of $98.56 million.Annual Revenue: Reached $180.1 millio

Discover Madrigal Pharmaceuticals' Q4 earnings insights, with revised estimates hinting at potential surprises.

Madrigal Pharmaceuticals Inc (MDGL) announced on February 21, 2025, that it will participate in the 45th Annual TD Cowen Health Care Conference on March 4, 2025

**media[546605]**